Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Reorganizes, Eliminates 20 Jobs

NEW YORK (GenomeWeb News) – WaferGen Bio-systems announced today a reorganization of its business, which resulted in the elimination of about 20 jobs during the first quarter.

The Fremont, Calif.-based firm said additional cost-cutting measures are being implemented, but it didn't provide details.

According to a recent 10-K filing with the US Securities and Exchange Commission, WaferGen ended 2011 with 54 employees, including 52 full-time employees.

The steps taken will reduce the monthly burn rate by 30 percent to about $700,000, WaferGen said, adding that the measures will provide it greater operational flexibility. The company ended the first quarter with approximately $12 million in cash, it said.

WaferGen President and CEO Ivan Trifunovich said in a statement that the firm's focus will be on its core competencies, "engineering and validation of a variety of chemistries to provide an open format for cost-effective gene expression and genotyping analysis, as well as target enrichment" for next-generation sequencing.

In its Form 10-K, WaferGen said its 2011 revenues fell more than four-fold to $522,931 from $2.2 million in 2010. Its net loss for 2011 increased to $13.1 million, or $.55 per share, from a net loss of $12.1 million, or $.35 per share, in 2010.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.